LB Pharmaceuticals Inc Common Stock (LBRX) Stock Score, Valuation & Financial Research

LB Pharmaceuticals Inc Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LBRX

LB Pharmaceuticals Inc Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 34.26. These figures are a research snapshot, not a buy or sell recommendation.

What LB Pharmaceuticals Inc Common Stock does

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

LB Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapies for neuropsychiatric diseases, relying on capital raises and financing activities to fund its ongoing clinical trials and operations.

Products and services

  • The company is developing LB-102, a small molecule oral product candidate currently in clinical trials for the treatment of schizophrenia, bipolar depression, and as an adjunctive treatment for major depressive disorder.

Brands and product families

  • LB-102 — Lead clinical-stage product candidate for schizophrenia and bipolar depression. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party contract research organizations to conduct and manage its clinical trials. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturers for the production of its clinical trial materials. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting significant neuropsychiatric indications Source

Business risks and research considerations

  • Limited operating history and history of operating losses Source
  • Dependence on the success of a single lead product candidate, LB-102 Source
  • Requirement for substantial additional capital to fund future operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LBRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 34.26
Market capitalization:
982.46M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -85.69M
Free cash flow:
USD -35.26M
Cash:
USD 283.11M
Total debt:
USD 5.22M
EPS:
USD -2.97

What stands out

  • Free cash flow is USD -35.26M, negative for the stored period.
  • The balance sheet shows USD 283.11M of cash versus USD 5.22M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 277.89M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LBRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LBRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LBRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LBRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LBRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research LBRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.